Yutaro Obara - Search Results

Year	Number of Results
2002	3
2003	1
2004	1
2005	3
2006	6
2007	5
2008	2
2009	4
2010	6
2011	6
2012	3
2013	7
2014	2
2015	2
2016	2
2017	3
2018	2
2019	3
2020	1
2021	1
2022	3
2023	1
2024	0

1

Midnolin is a confirmed genetic risk factor for Parkinson's disease.

Obara Y, Sato H, Nakayama T, Kato T, Ishii K. Obara Y, et al. Ann Clin Transl Neurol. 2019 Nov;6(11):2205-2211. doi: 10.1002/acn3.50914. Epub 2019 Oct 6. Ann Clin Transl Neurol. 2019. PMID: 31588691 Free PMC article.

2

Structural Variants of Midnolin, a Genetic Risk Factor for Parkinson's Disease, in a Yamagata Cohort.

Sato H, Ishii K, Obara Y. Sato H, et al. Among authors: obara y. Biol Pharm Bull. 2023;46(3):379-381. doi: 10.1248/bpb.b22-00776. Biol Pharm Bull. 2023. PMID: 36858566 Free article.

3

Midnolin is a novel regulator of parkin expression and is associated with Parkinson's Disease.

Obara Y, Imai T, Sato H, Takeda Y, Kato T, Ishii K. Obara Y, et al. Sci Rep. 2017 Jul 19;7(1):5885. doi: 10.1038/s41598-017-05456-0. Sci Rep. 2017. PMID: 28724963 Free PMC article.

4

Endocytic regulation of voltage-dependent potassium channels in the heart.

Ishii K, Norota I, Obara Y. Ishii K, et al. Among authors: obara y. J Pharmacol Sci. 2012;120(4):264-9. doi: 10.1254/jphs.12r12cp. Epub 2012 Nov 20. J Pharmacol Sci. 2012. PMID: 23165803 Free article. Review.

5

[Multiple functions of Gh/transglutaminase 2].

Obara Y, Ishii K. Obara Y, et al. Nihon Yakurigaku Zasshi. 2013 Apr;141(4):225. doi: 10.1254/fpj.141.225. Nihon Yakurigaku Zasshi. 2013. PMID: 23575431 Review. Japanese. No abstract available.

6

[Roles of ERK5 in neuronal cells].

Obara Y, Ishii K. Obara Y, et al. Nihon Yakurigaku Zasshi. 2013 Jun;141(6):354. doi: 10.1254/fpj.141.354. Nihon Yakurigaku Zasshi. 2013. PMID: 23749078 Review. Japanese. No abstract available.

7

[Roles of ERK5 in neuronal cells].

Obara Y. Obara Y. Nihon Yakurigaku Zasshi. 2013 May;141(5):251-5. doi: 10.1254/fpj.141.251. Nihon Yakurigaku Zasshi. 2013. PMID: 23665555 Review. Japanese. No abstract available.

8

Azelnidipine treatment reduces the expression of Ca_v1.2 protein.

Nasu F, Obara Y, Okamoto Y, Yamaguchi H, Kurakami K, Norota I, Ishii K. Nasu F, et al. Among authors: obara y. Life Sci. 2021 Mar 15;269:119043. doi: 10.1016/j.lfs.2021.119043. Epub 2021 Jan 13. Life Sci. 2021. PMID: 33453240

9

ERK5 inhibitor BIX02189 attenuates methamphetamine-induced hyperactivity by modulating microglial activation in the striatum.

Nakagawasai O, Takahashi K, Miura Y, Nemoto W, Obara Y, Tan-No K. Nakagawasai O, et al. Among authors: obara y. J Pharmacol Sci. 2022 Mar;148(3):326-330. doi: 10.1016/j.jphs.2022.01.009. Epub 2022 Jan 23. J Pharmacol Sci. 2022. PMID: 35177212 Free article.

10

The signaling pathway leading to extracellular signal-regulated kinase 5 (ERK5) activation via G-proteins and ERK5-dependent neurotrophic effects.

Obara Y, Nakahata N. Obara Y, et al. Mol Pharmacol. 2010 Jan;77(1):10-6. doi: 10.1124/mol.109.060236. Epub 2009 Oct 26. Mol Pharmacol. 2010. PMID: 19858097 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

59 results

Results by year

Search Page

Filters

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

Search Results

59 results

Results by year